Sensitivity to Intravenous Nicotine: Genetic Moderators
Diseases and Conditions Researched
Influence of OPRM1 A118G Status on Subjective Responses to IV Nicotine.
What is the purpose of this trial?
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
Click here for detailed participation information for this trial.
|Sponsors:||National Institute on Drug Abuse (NIDA); Yale University|
|Dates:||August 31, 2009|
|Last Updated:||February 1, 2013|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.